Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Boosting Chinese Healthcare Service Providers' Utilization of Smoking Cessation Interventions by 'WeChat WeQuit' Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03556774
Recruitment Status : Recruiting
First Posted : June 14, 2018
Last Update Posted : August 12, 2020
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Yanhui Liao, Sir Run Run Shaw Hospital

Brief Summary:
In this single-blind, randomized trial, undertaken in China with 8-week interventions and follow-up to 52 weeks, about 2,200 providers will be randomly allocated to the intervention or control group.

Condition or disease Intervention/treatment Phase
Smoking Cessation Intervention Smoking Abstinence Behavioral: 'WeChat WeQuit' smoking cessation training program Not Applicable

Detailed Description:

Previous studies have been showed that providing behavioral and pharmacotherapy interventions for cigarette smoking patients was effective but rare among Chinese healthcare service providers. In order to minimize the huge gap between the shortage and demand for smoking cessation training program and smoking cessation service, this 'WeChat WeQuit' smoking cessation training program has been designed to assess whether it will increase Chinese healthcare service providers' utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation or not.

In this single-blind, randomized trial, about 2200 HSPs will be randomly selected (by randomizeR, https://CRAN.R-project.org/package=randomizeR) to 8-week intervention (behavioral and pharmacotherapy interventions for cigarette smoking patients to help them quit smoking) group or control group that only communicates without any standard smoking cessation practices related messages, and follow-up to 52 weeks. The trial will be carried out in into two phases, the first phase is the pilot study (n=200, 8-week intervention and follow-up to 16 weeks) and the second is the main study (n=2000, 8-week intervention and follow-up to 52 weeks). It is hypothesized that 'WeChat WeQuit' training program will improve Chinese HSPs' utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation and increase quit rate for smoking patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Health Services Research
Official Title: Boosting Chinese Healthcare Service Providers' Utilization of Behavioral and Pharmacotherapy Interventions for Cigarette Smoking Cessation by 'WeChat WeQuit' Program
Actual Study Start Date : April 1, 2019
Estimated Primary Completion Date : August 30, 2021
Estimated Study Completion Date : August 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: With smoking cessation training
Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
Behavioral: 'WeChat WeQuit' smoking cessation training program
Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.

No Intervention: Without smoking cessation training
Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.



Primary Outcome Measures :
  1. The effectiveness of 'WeChat WeQuit' training program. [ Time Frame: 52 weeks ]
    The utilization rate (i.e. rate=smokers treated divided by smokers seen) of behavioral and pharmacotherapy interventions by HSP for smoking patients from 8 to 52-week.


Secondary Outcome Measures :
  1. Prevalence of smoking abstinence [ Time Frame: 24 weeks ]
    The proportion of smoking patients with 7-day point prevalence smoking abstinence (not even a puff of smoke, for the last 7 days) at 4, 8, 12, 16, 20 and continuously abstinence assessed at 24-weeks follow-up.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Chinese-speaking healthcare service providers
  2. Know how to use WeChat
  3. Use WeChat on a daily basis
  4. Willing to provide informed consent to participate in the study -

Exclusion Criteria:

  1. Non-Chinese speakers
  2. Not healthcare service providers
  3. Do not use WeChat
  4. Unwilling to participate in the study -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03556774


Contacts
Layout table for location contacts
Contact: Yanhui Liao, MD +8615116225099 tangliaoyanhui@163.com

Locations
Layout table for location information
China, Zhejiang
Yanhui Liao Recruiting
Hangzhou, Zhejiang, China, 310016
Contact: Yanhui Liao, MD    8615116225099    tangliaoyanhui@163.com   
Sponsors and Collaborators
Sir Run Run Shaw Hospital
Pfizer
Layout table for additonal information
Responsible Party: Yanhui Liao, Attending Psychiatrist, Sir Run Run Shaw Hospital
ClinicalTrials.gov Identifier: NCT03556774    
Other Study ID Numbers: 2017S094
First Posted: June 14, 2018    Key Record Dates
Last Update Posted: August 12, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No